Skip to Main Content
Contribute Try STAT+ Today

In another bid to address the cost of prescription medicines, Takeda Pharmaceuticals (TAK) and Point32Health have reached a deal in which the drug maker will offer a “significant rebate” for a lung cancer treatment if the medication proves ineffective for patients.

Specifically, the deal involves Alunbrig, which is approved to treat non-small cell lung cancer. If a patient covered by Point32Health — the second-largest health plan in New England — does not remain on the drug for three months or more due to effectiveness or tolerability, Takeda will return an unspecified amount of money to the insurer. The drug has a $17,000 list price for a month’s treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment